Few real‐life studies evaluated long‐term apremilast therapy in the variable spectrum of
clinical‐anamnestic features which can be found in psoriatic arthritis (PsA) patients. This real …

Objective. To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4
inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior …

Objectives We aimed to evaluate the baseline characteristics, the reasons for prescription,
and the effectiveness/safety profile of real-life apremilast for the treatment of psoriatic arthritis …

Objective To evaluate the efficacy and safety of apremilast, a novel, orally available small
molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Objective Psoriatic arthritis (PsA) requires long‐term treatment, yet safety concerns and
monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic …

Background The efficacy and safety of apremilast were assessed in patients with psoriatic
arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3) …

Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints that occurs in patients
with psoriasis. The spectrum of PsA includes arthritis, dactylitis, enthesitis, axial involvement …

Psoriasis is a multifactorial, chronic, auto‐inflammatory disease, with a worldwide
prevalence of around 2%, subtended by robust genetic predisposition and autoimmune …